Molecular Mechanisms of Oncogenesis
ITT Core Research Laboratory (CRL)
Villa delle Rose
via Cosimo il Vecchio 2, 50139 Firenze
Tel. +39 055 32697858
Fax. +39 055 32697879
Principal Investigator: Silvo Conticello, MD
Main Research Themes
The Molecular Mechanisms of Oncogenesis Unit started its research activities in January 2008. Our
research is focused on the identification and characterization of factors and pathways involved in the
onset of genetic alterations in cancer.
Role of activation-induced deaminase in oncogenesis
Cancer is the outcome of a multistep path that progressively leads to uncontrolled cellular growth.
Underlying this progression of events is the presence of genetic alterations or mutations that provide
the framework, characterizing the type and evolution of the tumor. Mostly, we have access only to the
ending point of this path - with the diagnosis of cancer - and it is not easy to intervene in this succession
of events. However, understanding the factors and processes leading to the genetic alterations can
improve our diagnostic and therapeutic options by a finer characterization of the tumorigenesis - the
final aim being a more targeted treatment.
Surprisingly there is a class of enzymes, the AID/APOBECs, whose only role is to introduce mutations
in DNA molecules (a). The founder member, Activation Induced Deaminase (AID), is a DNA mutator
that, after recruitment to the transcribed immunoglobulin gene, deaminates cytosine residues to uracil.
The deamination, followed by the recruitment of the DNA repair machinery, results in the mutation
and recombination of the antibody genes, thus initiating the antigen-driven antibody diversification
AID is a powerful tool to improve the immune response, but its ability to mutate DNA represents a
double edged sword: transgenic mice constitutively expressing AID develop cancer (c) and there is
increasing evidence linking AID to the onset of mature B-cell lymphomas (d). These tumors arise during
the antigen dependent stages of the antibody gene diversification, and are often characterized by
chromosomal translocations involving the IgH gene. While such chromosomal aberrations have been
long hypothesized to be linked to the antibody gene diversification processes, only recently it has been
proven that AID triggers c-myc/IgH translocations (a common trait in Burkitt's lymphomas) in Balb/c
mice by targeting both the IgH locus and the c-myc locus. Moreover, expression of AID is needed in
order to develop germinal center derived lymphomas in cancer-prone mice.
In addition to the B-cell lineage, AID is able to induce cancer in other experimental settings: ectopic
expression of AID in transgenic mice induces cancer, and AID could be involved in the onset of
chromosomal translocations specific for prostatic cancer in a prostate cell line.
At the current state of research, the specific processes by which AID can ultimately trigger cancer are not
known. AID could induce DNA lesions somehow mimicking those occuring during B-cell development;
these lesions could originate from a genome-wide mistargeting; or cells could be affected by changes
in the methylation status of mistargeted genes. Indeed, much of the pathological effects of AID might
depend on factors and pathways involved in its regulation: inflammation and inflammation-related
signaling pathways can trigger expression of AID in B-cells and in other cell types. Unfortunately, very
little is known about the crossroad between regulation of AID and its targeting of the DNA.
The main objective of our research is to investigate the role of AID in the onset and progression of
human cancer through two converging approaches:
- Identification and characterization of molecules and pathways controlling the function of AID: while
overexpression of AID induces a generalized increase in mutations, under physiological conditions
the primary target for AID is a specific region in the immunoglobulin locus. This suggests the
existence of a targeting machinery and the possibility that AID misregulation could lead to DNA
lesions and tumorigenesis. During my postdoctoral period at the MRC-LMB, I identified CTNNBL1,
a spliceosome-associated molecule, as a specific interactor of AID involved in its targeting (e).
Mutations in AID that interfere with the interaction lead to defects both in somatic hypermutation and
class switch recombination. While the role of CTNNBL1 has not yet been clarified, its association
with the spliceosome is intriguing: this is the first molecule specifically linking the targeting of AID to
the mRNA processing machinery.
To this aim, we use a number of tools, ranging from biochemical and bacterial assays to cellular
assays. In particular, DT40 cells - a chicken lymphoma cell line - which allow efficient gene targeting
and provide a reliable assay system for AID function, and CH12F3 cells, a murine lymphoma clone
in which AID can be induced to trigger IgM to IgA class switch recombination. In these models,
we can analyze both the ability of AID to initiate the antibody diversification processes and its
role in the mistargeting of somatic mutations and induction of cancer-like c-myc/IgH chromosomal
translocations, analogous to those found in Burkitt's lymphoma. The information gathered through
this research will be then used in transgenic mice to investigate whether forced expression of AID
mutants and AID regulators makes B-cells more/less susceptible to tumorigenesis.
- Analysis of human hematopoietic tumors: to assess whether distinct patterns of expression are
associated with specific types of cancer and their prognosis, and to test our findings on the regulatory
pathways of AID directly on the cancer tissues and thus evaluate their relevance to the biology
of cancer. Constitutive expression of AID has been reported in a number of lymphoproliferative
malignancies. In some cases, such as in chronic lymphocytic leukemia, AID is, paradoxically,
expressed tumors with unmutated immunoglobulin V genes, while it seems absent from the ones
with mutated immunoglobulin genes, which have a better prognosis. With AID expression being
linked to the prognosis in B-cell lineage tumors, we are investigating whether AID is merely a relic
of the developmental stage at the origin of the tumor or it plays an active role in the progression of
the cancer. Whichever the answer, we will try to correlate the presence of AID to specific neoplastic
subpopulations and to the relative prognosis. This approach will naturally complement the molecular
dissection of AID regulatory pathways, as we will be able to test our findings directly on the neoplastic
samples and thus evaluate their relevance to the biology of cancer.
- Conticello SG: The AID/APOBEC family of nucleic acid mutators. Genome Biol 2008; 9: 229.
- Di Noia JM, Neuberger MS: Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem 2007; 76: 1-22.
- Okazaki IM, Kotani A, Honjo T: Role of AID in tumorigenesis. Adv Immunol 2007; 94: 245-73.
- Pérez-Durán P, de Yebenes VG, Ramiro AR: Oncogenic events triggered by AID, the adverse effect of antibody diversification. Carcinogenesis 2007; 28: 2427-33.
- Conticello SG, Ganesh K, Xue K, Lu M, Rada C, Neuberger MS: Interaction between antibody-diversification enzyme AID and spliceosome-associated factor CTNNBL1. Mol Cell 2008; 31: 474-84.
With Units within ITT
- Department of Oncology, Azienda Ospedaliero Universitaria Careggi (AOU Careggi), Firenze
- Hematology and Transplant Unit, University of Siena
With other Italian and Foreign Institutions/Organizations
- Medical Research Council, Laboratory of Molecular Biology, Cambridge (UK)
- LaRue RS, Andrésdóttir V, Blanchard Y, et al: Guidelines for naming nonprimate APOBEC3 genes and proteins. J Virol 2009; 83: 494-7.
- Conticello SG, Langlois MA, Yang Z, Neuberger MS: DNA deamination in immunity: AID in the context of its APOBEC relatives. Adv Immunol 2007; 94: 37-73.
- Conticello SG, Thomas CJ, Petersen-Mahrt SK, Neuberger MS: Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol Biol Evol 2005; 22: 367-77.
- Langlois MA, Beale RC, Conticello SG, Neuberger MS: Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res 2005; 33: 1913-23.
- Conticello SG, Harris RS, Neuberger MS: The vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol 2003; 13: 2009-13.
- Conticello SG, Kowalsman ND, Jacobsen C, et al: The prodomain of a secreted hydrophobic mini-protein facilitates its export from the endoplasmic reticulum by hitchhiking on sorting receptors. J Biol Chem 2003; 278: 26311-4.
- Tcherpakov M, Bronfman FC, Conticello SG, et al: The p75 neurotrophin receptor interacts with multiple MAGE proteins. J Biol Chem 2002; 277: 49101-4.
- Conticello SG, Gilad Y, Avidan N, Ben-Asher E, Levy Z, Fainzilber M: Mechanisms for evolving hypervariability: the case of conopeptides. Mol Biol Evol 2001; 18: 120-31.
- Jaaro H, Beck G, Conticello SG, Fainzilber M: Evolving better brains: a need for neurotrophins? Trends Neurosci 2001;24: 79-85.
^ torna all'inizio